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Understanding Hereditary Hemochromatosis
Kari Davidson, RN, BSN,
Otterbein University, Westerville, Ohio

Signs and Symptoms

Introduction
One of the most common genetic diseases,
hereditary hemochromatosis is a disruption
of iron regulation in the body. Its geographic
distribution is worldwide, but it is most
common in those of northern European
origin. (Roach and Di Palma, 2012).
Occurrence is rare in other racial or ethnic
groups. (Emanuele, Tuason, & Edwards,
2014).
Symptoms are due to significant iron
overload, normally as a result of HFE gene
mutation. (Centers for Disease Control and
Prevention, 2010). The HFE gene plays an
important role in regulating iron absorption
in the GI tract, transport, and storage.
(Emanuele, et al., 2014).
If excess iron accumulates in vital organs,
cirrhosis, bone and joint disease, diabetes,
other endocrine disorders and heart disease
can result. (Crownover & Covey, 2013).
Although penetrance (exhibition of
phenotype, or clinical symptoms) varies in
those with the genetic mutation, those who
have the HFE mutation are much more
genetically susceptible to iron overload as it
manifests in hereditary hemochromatosis.
Patients can present with nonspecific
complaints such as weakness, fatigue,
changes in mental status, and arthralgia, so
hereditary hemochromatosis can be missed
or misdiagnosed if iron study testing is not
performed. The most common route to
diagnosis is through routine office visits or
investiation of common complaints. (Brissot,
Ball, Rofail, Cannon, & We Jin, 2011). In
some cases, but not all, genetic testing may be
appropriate. Other forms of iron overload
must be considered as well when making a
differential diagnosis.
Hereditary hemochromatosis has an
autosomal recessive pattern; a carrier father
and carrier mother have a 1 in 4 chance of
having a homozygous child and a 50% chance
of having a heterozygous (carrier) child.
About 75% of homozygotes have expression
of the disease with elevated serum ferritin
levels, although there is some controversy as
to the proportion which develops clinically
significant disease. Environmental and
genetic factors may interact to influence
expression of hereditary
hemochromatosis.(Roach & DiPalma,2012).
Approximately 1 million people in the United
States are homozygous for the mutation.
(National Heart Lung and Blood Institute,
2011). According to Emauele, et al., (2014),
1 in 8 to 1 in 10 whites in the United States
may be carriers of the affected HFE gene.

•

Slow progression. Many are asymptomatic.

•

Age of presentation typically 40-60 in men, postmenopause in women.

•

Early signs and symptoms tend to be general and
may include:
•
Weight loss
•
Fatigue
•
Joint discomfort
•
Abdominal discomfort
•
Weakness
•
Restless leg syndrome
•
Hair loss
•
Loss of libido
•
Changes in mental status/depression
(Rojas-Roldan & Wilkins, 2014).

•

•

Underlying Pathophysiology
Hereditary hemochromatosis encompasses a range of iron overload disorders
which are due to genetic misregulation of iron acquisition. (Vujic, 2014).
The specific mutation which accounts for most cases of hereditary
hemochromatosis occurs at the major histocompatibility complex (MHC) region
on the short arm of chromosome 6. A missense mutation is found at this locus in
80% of hereditary hemochromatosis patients. The mutation results in a cysteine
to tyrosine substitution at amino acid 282 of the HFE protein (C282Y). (Vujic,
2014). This form of the disease is known as “hemochromatosis type 1”.
(Cherfane, Hollenbeck, Go, & Brown, 2013).

With untreated advanced disease, patients may
present with:
•
Hepatitis
•
Hepatomegaly
•
Hepatocellular cancer
•
Cirrhosis
•
Arrhythmias
•
Arthritis, particularly of the second or
third metacarpophalangeal joints.
•
Cardiomyopathy
•
Bronzed, hyperpigmented skin
•
Diabetes Mellitus
•
Hypogonadism
Laboratory findings:
•
Transferrin Saturation >45%
•
Serum ferritin levels > 300 ng/mL
•
Serum ferritin >200 in
premenopausal females
(Centers for Disease Control and
Prevention, 2010).

Figure 1. The hand on the right shows hyperpigmentation, or
bronzing of the skin, due to iron overload in hereditary
hemochromatosis.
Image Courtesy of Consultant 360.com

Significance of Pathophysiology
Iron is “essential for cell metabolism and is a constituent of hemoproteins, such as
hemoglobin, myoglobin, and cytochrome.” (Crownover & Covey, 2013, p. 183). Any
pathological process which disrupts the carefully regulated iron balance of the body
will eventually affect entire body systems. Hereditary hemochromatosis, with an
insidious onset and often generalized presenting systems, could slide under the radar
or be misdiagnosed until more severe manifestations of iron overload appear. Endorgan damage or clinical manifestations of hereditary hemochromatosis occur in
approximately 10 percent of persons homozygous for C282Y. (Crownover & Covey,
2013). Considering the number of those homozygous for the disease, this is a
significant portion of the population.
Hereditary hemochromatosis is associated with an increased risk for malignancies,
such as hepatocarcinoma and breast cancer. “Approximately 6 percent of patients
with hemochromatosis and cirrhosis develop hepatocellular carcinoma; this
represents a 20-fold increased lifetime risk over the general population…”
(Crownover & Covey, 2013, p. 183).
If untreated, hereditary hemochromatosis can lead to irreversible organ damage.
Prognosis is worsened in those who develop cirrhosis, diabetes, or cardiomyopathy.
“The 5-year survival rate in those who have untreated hereditary hemochromatosis
and cirrhosis is reduced by 50 percent compared with those who do not have
cirrhosis.” (Crownover & Covey, 2013, p. 184.)
It is important to understand the progression of the disease, the broad spectrum of
phenotypical expression, and the underlying genetic, hormonal, and environmental
interplay at work in this disease in order to recognize and anticipate how body
systems may be affected.

Implications for
Nursing Care
Figure 2. Normal HFE Gene Compared to C282Y Mutation in Hemochromatosis Type 1
www.CDC.gov
Normally, hepatocytes secrete the regulatory hormone hepcidin in response to excess
iron intake. Hepcidin, a peptide hormone, decreases intestinal iron absorption by
enterocytes and decreases iron release by macrophages, contributing to whole-body
iron homeostasis. The HFE genetic defect alters expression of the protein which
regulates hepcidin. (Crownover and Covey, 2013). Patients with hereditary
hemochromatosis have insufficient hepcidin concentrations, resulting in unregulated
iron absorption, mobilization, distribution, and storage. (Emanuele, et al., 2014). A
major means of iron export from the body is the ferroportin-hepcidin pathway.
Hepcidin binds with ferroportin, which is located on enterocytes (GI tract),
macrophages, and hepatocytes, and regulates release of cellular iron. This pathway is
disrupted due to low hepcidin levels. (Emanuele, et al., 2014).
Iron begins to enter the plasma at a high rate, leading to increased transferrin
saturation and ferritin levels, and over time builds up in body tissues and organs,
causing damage. (Emanuele, et al., 2014). Major organs adversely affected by iron
deposition are the liver, pancreas, heart, pituitary gland, testicles, joints, and skin. Many
of the presenting signs and symptoms are due to disruption of the normal function of
these organs.
Main pathological findings in the liver are fibrosis and cirrhosis. Iron overload may
contribute to the risk of diabetes, as it is associated with increased hepatic glucose
production and metabolic inflexibility, both characteristics of type II diabetes. (Huang, et
al., 2011).
Less common forms of hereditary hemochromatosis (types 2-4) are caused by
mutations in genes other than HFE which help control iron regulation. (Cherfane, et al.,
2013). A less common form of the type 1 mutation is at H63D, another locus of the HFA
gene. Compound heterozygotes (those carrying the C282Y defect and another
autosomal recessive mutation which could affect iron regulation) are susceptible to
developing iron overload. accounting in part for variability in expression. Non-genetic
factors such as alcoholism may contribute to disease progression.

Although patients may rarely present with the
classic triad of symptoms described by Trousseau
(bronzed skin, diabetes mellitus, and
hepatomegaly), practitioners should also consider
hereditary hemochromatosis in patients with
nonspecific symptoms such as fatigue, arthralgia,
weakness, cognition changes, or depression in
conjunction with elevated transferrin saturation
and ferritin levels. Medical professionals should
be aware that expression of the disease is
influenced not only by genetics but also by other
factors such as alcoholism, iron rich diet,
menstruation, age, and other diseases of iron
malabsorption such as celiac disease.
If a patient is of northern European ancestry,
this genetic disorder may be of particular concern
in those with relevant symptoms.
There is debate among researchers about the
usefulness of genetic testing. Population screening
for the HFE mutation is not recommended by the
Centers for Disease Control and Prevention, but
should be performed in first degree relatives of
those with HFE hemochromatosis. (Crownover &
Covey, 2013). According to the Centers for Disease
Control and Prevention, iron status testing is
considered more clinically relevant than genetic
testing for identifying those who have
hemochromatosis (2010). Many times this
disease is diagnosed in patients after routine office
visits, so general practitioners should be aware of
its nuances.

Conclusion
Hereditary hemochromatosis
is the most common genetic
disorder affecting whites in the
United States. Most of those
who are homozygous for the
mutation are asymptomatic.
Manifestation of symptoms
correlates with body iron
content, with symptoms
worsening as iron levels
increase. At the beginning of
disease progression, patients
may have nonspecific
complaints, but may progress
to signs of organ damage and
early death.
Treatment for iron overload
in hereditary hemochromatosis
includes decreasing dietary
iron intake and phlebotomy to
decrease serum ferritin to the
desired level. It is imperative
that health practitioners know
how to recognize and respond
to hereditary hemochromatosis,
preferably before irreversible
organ damage occurs.
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